References
World Health Organization (2019) International statistical classification of diseases and related health problems, 11th edn. https://icd.who.int/. Accessed 10 June 2023
American Psychiatric Association (2022) Diagnostic and statistical manual of mental disorders, 5th edn, text rev. American Psychiatric Association. https://doi.org/10.1176/appi.books.97808904257
Austin A, Craig SL, D’Souza S, McInroy LB (2022) Among transgender youth: elucidating the role of interpersonal risk factors. J Interpers Violence 37(5–6):NP2696–NP2718. https://doi.org/10.1177/08862605209155542
Campbell T, Rodgers YVM (2023) Conversion therapy, suicidality, and running away: an analysis of transgender youth in the US. J Health Econ 89:102750. https://doi.org/10.1016/j.jhealeco.2023.102750
Coleman E, Radix AE, Bouman WP et al (2022) Standards of care for the health of transgender and gender diverse people, version 8. Int J Transgend Health 23(Suppl 1):S1–S259. https://doi.org/10.1080/26895269.2022.2100644
Hembree WC, Cohen-Kettenis PT, Gooren L et al (2017) Endocrine treatment of gender-dysphoric/gender-incongruent persons: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 102(11):3869–3903. https://doi.org/10.1210/jc.2017-01658
Fisher AD, Ristori J, Bandini E et al (2014) Medical treatment in gender dysphoric adolescents endorsed by SIAMS-SIE-SIEDP-ONIG. J Endocrinol Invest 37(7):675–687. https://doi.org/10.1007/s40618-014-0077-6
Lee WG, Butler G, Carmichael P et al (2023) Urological and gynaecological considerations for the use of gonadotropin-releasing hormone analogues in transgender and nonbinary adolescents: a narrative review. Eur Urol Focus 9(1):35–41. https://doi.org/10.1016/j.euf.2022.11.002
Tordoff DM, Wanta JW, Collin A, Stepney C, Inwards-Breland DJ, Ahrens K (2022) Mental health outcomes in transgender and nonbinary youths receiving gender-affirming care. JAMA Netw Open 5(2):e220978. https://doi.org/10.1001/jamanetworkopen.2022.0978
Carmichael P, Butler G, Masic U et al (2021) Short-term outcomes of pubertal suppression in a selected cohort of 12 to 15 year old young people with persistent gender dysphoria in the UK. PLoS ONE 16(2):e0243894. https://doi.org/10.1371/journal.pone.0243894
Schagen SEE, Wouters FM, Cohen-Kettenis PT, Gooren LJ, Hannema SE (2020) Bone development in transgender adolescents treated with GnRH analogues and subsequent gender-affirming hormones. J Clin Endocrinol Metab 105(12):e4252–e4263. https://doi.org/10.1210/clinem/dgaa604
Vlot MC, Klink DT, den Heijer M, Blankenstein MA, Rotteveel J, Heijboer AC (2017) Effect of pubertal suppression and cross-sex hormone therapy on bone turnover markers and bone mineral apparent density (BMAD) in transgender adolescents. Bone 95:11–19. https://doi.org/10.1016/j.bone.2016.11.008
Schagen SE, Cohen-Kettenis PT, Delemarre-van de Waal HA, Hannema SE (2016) Efficacy and safety of gonadotropin-releasing hormone agonist treatment to suppress puberty in gender dysphoric adolescents. J Sex Med 13(7):1125–1132. https://doi.org/10.1016/j.jsxm.2016.05.004
Klaver M, de Mutsert R, Wiepjes CM et al (2018) Early hormonal treatment affects body composition and body shape in young transgender adolescents. J Sex Med 15(2):251–260. https://doi.org/10.1016/j.jsxm.2017.12.009
Klink D, Bokenkamp A, Dekker C, Rotteveel J (2015) Arterial hypertension as a complication of triptorelin treatment in adolescents with gender dysphoria. Endocrinol Metab Int J 2(1):36–38. https://doi.org/10.15406/emij.2015.02.00008
Perl L, Segev-Becker A, Israeli G, Elkon-Tamir E, Oren A (2020) Blood pressure dynamics after pubertal suppression with gonadotropin-releasing hormone analogs followed by testosterone treatment in transgender male adolescents: a pilot study. LGBT Health 7(6):340–344. https://doi.org/10.1089/lgbt.2020.0026
Moreira Allgayer RMC, Borba GDS, Moraes RS, Ramos RB, Spritzer PM (2023) The effect of gender-affirming hormone therapy on the risk of subclinical atherosclerosis in the transgender population: a systematic review. Endocr Pract 29(6):498–507. https://doi.org/10.1016/j.eprac.2022.12.017
Howerton I, Harris JK (2022) Transgender identity and cardiovascular disease. Transgend Health 7(5):407–415. https://doi.org/10.1089/trgh.2020.0188
Valentine A, Davis S, Furniss A et al (2022) Multicenter analysis of cardiometabolic-related diagnoses in transgender and gender-diverse youth: a PEDSnet study. J Clin Endocrinol Metab 107(10):e4004–e4014. https://doi.org/10.1210/clinem/dgac469
Levine SB, Brown GR, Coleman E et al (1998) The standards of care for gender identity disorders—Fifth edition. J Psychol Human Sex 11(2):1–34. https://doi.org/10.1300/J056v11n02_01
Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA et al (2009) Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 94(9):3132–3154. https://doi.org/10.1210/jc.2009-0345
de Vries ALC, Hannema SE (2023) Growing Evidence and remaining questions in adolescent transgender care. N Engl J Med 388(3):275–277. https://doi.org/10.1056/NEJMe2216191
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ristori, J., Motta, G., Meriggiola, M.C. et al. A comment from SIGIS, SIE and SIAMS: “Puberty blockers in transgender adolescents—a matter of growing evidence and not of ideology”. J Endocrinol Invest 47, 479–481 (2024). https://doi.org/10.1007/s40618-023-02173-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40618-023-02173-6